Schmidt, AF and Swerdlow, DI and Holmes, MV and Patel, RS and Fairhurst-Hunter, Z and Lyall, DM and Hartwig, FP and Horta, BL and Hyppönen, E and Power, C and Moldovan, M and van Iperen, E and Hovingh, GK and Demuth, I and Norman, K and Steinhagen-Thiessen, E and Demuth, J and Bertram, L and Liu, T and Coassin, S and Willeit, J and Kiechl, S and Willeit, K and Mason, D and Wright, J and Morris, R and Wanamethee, G and Whincup, P and Ben-Shlomo, Y and McLachlan, S and Price, JF and Kivimaki, M and Welch, C and Sanchez-Galvez, A and Marques-Vidal, P and Nicolaides, A and Panayiotou, AG and Onland-Moret, NC and van der Schouw, YT and Matullo, G and Fiorito, G and Guarrera, S and Sacerdote, C and Wareham, NJ and Langenberg, C and Scott, R and Luan, J and Bobak, M and Malyutina, S and Pająk, A and Kubinova, R and Tamosiunas, A and Pikhart, H and Husemoen, LLN and Grarup, N and Pedersen, O and Hansen, T and Linneberg, A and Simonsen, KS and Cooper, J and Humphries, SE and Brilliant, M and Kitchner, T and Hakonarson, H and Carrell, DS and McCarty, CA and Kirchner, HL and Larson, EB and Crosslin, DR and de Andrade, M and Roden, DM and Denny, JC and Carty, C and Hancock, S and Attia, J and Holliday, E and O'Donnell, M and Yusuf, S and Chong, M and Pare, G and van der Harst, P and Said, MA and Eppinga, RN and Verweij, N and Snieder, H and Christen, T and Mook-Kanamori, DO and Gustafsson, S and Lind, L and Ingelsson, E and Pazoki, R and Franco, O and Hofman, A and Uitterlinden, A and Dehghan, A and Teumer, A and Baumeister, S and Dörr, M and Lerch, MM and Völker, U and Völzke, H and Ward, J and Pell, JP and Smith, DJ and Meade, T and Maitland-van der Zee, AH and Baranova, EV and Young, R and Ford, I and Campbell, A and Padmanabhan, S and Bots, ML and Grobbee, DE and Froguel, P and Thuillier, D and Balkau, B and Bonnefond, A and Cariou, B and Smart, M and Bao, Y and Kumari, M and Mahajan, A and Ridker, PM and Chasman, DI and Reiner, AP and Lange, LA and Ritchie, MD and Asselbergs, FW and Casas, J-P and Keating, BJ and Preiss, D and Hingorani, AD and Sattar, N (2017) PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. The Lancet Diabetes and Endocrinology, 5 (2). pp. 97-105. DOI https://doi.org/10.1016/S2213-8587(16)30396-5
Schmidt, AF and Swerdlow, DI and Holmes, MV and Patel, RS and Fairhurst-Hunter, Z and Lyall, DM and Hartwig, FP and Horta, BL and Hyppönen, E and Power, C and Moldovan, M and van Iperen, E and Hovingh, GK and Demuth, I and Norman, K and Steinhagen-Thiessen, E and Demuth, J and Bertram, L and Liu, T and Coassin, S and Willeit, J and Kiechl, S and Willeit, K and Mason, D and Wright, J and Morris, R and Wanamethee, G and Whincup, P and Ben-Shlomo, Y and McLachlan, S and Price, JF and Kivimaki, M and Welch, C and Sanchez-Galvez, A and Marques-Vidal, P and Nicolaides, A and Panayiotou, AG and Onland-Moret, NC and van der Schouw, YT and Matullo, G and Fiorito, G and Guarrera, S and Sacerdote, C and Wareham, NJ and Langenberg, C and Scott, R and Luan, J and Bobak, M and Malyutina, S and Pająk, A and Kubinova, R and Tamosiunas, A and Pikhart, H and Husemoen, LLN and Grarup, N and Pedersen, O and Hansen, T and Linneberg, A and Simonsen, KS and Cooper, J and Humphries, SE and Brilliant, M and Kitchner, T and Hakonarson, H and Carrell, DS and McCarty, CA and Kirchner, HL and Larson, EB and Crosslin, DR and de Andrade, M and Roden, DM and Denny, JC and Carty, C and Hancock, S and Attia, J and Holliday, E and O'Donnell, M and Yusuf, S and Chong, M and Pare, G and van der Harst, P and Said, MA and Eppinga, RN and Verweij, N and Snieder, H and Christen, T and Mook-Kanamori, DO and Gustafsson, S and Lind, L and Ingelsson, E and Pazoki, R and Franco, O and Hofman, A and Uitterlinden, A and Dehghan, A and Teumer, A and Baumeister, S and Dörr, M and Lerch, MM and Völker, U and Völzke, H and Ward, J and Pell, JP and Smith, DJ and Meade, T and Maitland-van der Zee, AH and Baranova, EV and Young, R and Ford, I and Campbell, A and Padmanabhan, S and Bots, ML and Grobbee, DE and Froguel, P and Thuillier, D and Balkau, B and Bonnefond, A and Cariou, B and Smart, M and Bao, Y and Kumari, M and Mahajan, A and Ridker, PM and Chasman, DI and Reiner, AP and Lange, LA and Ritchie, MD and Asselbergs, FW and Casas, J-P and Keating, BJ and Preiss, D and Hingorani, AD and Sattar, N (2017) PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. The Lancet Diabetes and Endocrinology, 5 (2). pp. 97-105. DOI https://doi.org/10.1016/S2213-8587(16)30396-5
Schmidt, AF and Swerdlow, DI and Holmes, MV and Patel, RS and Fairhurst-Hunter, Z and Lyall, DM and Hartwig, FP and Horta, BL and Hyppönen, E and Power, C and Moldovan, M and van Iperen, E and Hovingh, GK and Demuth, I and Norman, K and Steinhagen-Thiessen, E and Demuth, J and Bertram, L and Liu, T and Coassin, S and Willeit, J and Kiechl, S and Willeit, K and Mason, D and Wright, J and Morris, R and Wanamethee, G and Whincup, P and Ben-Shlomo, Y and McLachlan, S and Price, JF and Kivimaki, M and Welch, C and Sanchez-Galvez, A and Marques-Vidal, P and Nicolaides, A and Panayiotou, AG and Onland-Moret, NC and van der Schouw, YT and Matullo, G and Fiorito, G and Guarrera, S and Sacerdote, C and Wareham, NJ and Langenberg, C and Scott, R and Luan, J and Bobak, M and Malyutina, S and Pająk, A and Kubinova, R and Tamosiunas, A and Pikhart, H and Husemoen, LLN and Grarup, N and Pedersen, O and Hansen, T and Linneberg, A and Simonsen, KS and Cooper, J and Humphries, SE and Brilliant, M and Kitchner, T and Hakonarson, H and Carrell, DS and McCarty, CA and Kirchner, HL and Larson, EB and Crosslin, DR and de Andrade, M and Roden, DM and Denny, JC and Carty, C and Hancock, S and Attia, J and Holliday, E and O'Donnell, M and Yusuf, S and Chong, M and Pare, G and van der Harst, P and Said, MA and Eppinga, RN and Verweij, N and Snieder, H and Christen, T and Mook-Kanamori, DO and Gustafsson, S and Lind, L and Ingelsson, E and Pazoki, R and Franco, O and Hofman, A and Uitterlinden, A and Dehghan, A and Teumer, A and Baumeister, S and Dörr, M and Lerch, MM and Völker, U and Völzke, H and Ward, J and Pell, JP and Smith, DJ and Meade, T and Maitland-van der Zee, AH and Baranova, EV and Young, R and Ford, I and Campbell, A and Padmanabhan, S and Bots, ML and Grobbee, DE and Froguel, P and Thuillier, D and Balkau, B and Bonnefond, A and Cariou, B and Smart, M and Bao, Y and Kumari, M and Mahajan, A and Ridker, PM and Chasman, DI and Reiner, AP and Lange, LA and Ritchie, MD and Asselbergs, FW and Casas, J-P and Keating, BJ and Preiss, D and Hingorani, AD and Sattar, N (2017) PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. The Lancet Diabetes and Endocrinology, 5 (2). pp. 97-105. DOI https://doi.org/10.1016/S2213-8587(16)30396-5
Abstract
Background Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabetes, which in no way offsets their substantial benefits. We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk. Methods In this mendelian randomisation study, we used data from cohort studies, randomised controlled trials, case control studies, and genetic consortia to estimate associations of PCSK9 genetic variants with LDL cholesterol, fasting blood glucose, HbA1c, fasting insulin, bodyweight, waist-to-hip ratio, BMI, and risk of type 2 diabetes, using a standardised analysis plan, meta-analyses, and weighted gene-centric scores. Findings Data were available for more than 550 000 individuals and 51 623 cases of type 2 diabetes. Combined analyses of four independent PCSK9 variants (rs11583680, rs11591147, rs2479409, and rs11206510) scaled to 1 mmol/L lower LDL cholesterol showed associations with increased fasting glucose (0·09 mmol/L, 95% CI 0·02 to 0·15), bodyweight (1·03 kg, 0·24 to 1·82), waist-to-hip ratio (0·006, 0·003 to 0·010), and an odds ratio for type diabetes of 1·29 (1·11 to 1·50). Based on the collected data, we did not identify associations with HbA1c (0·03%, −0·01 to 0·08), fasting insulin (0·00%, −0·06 to 0·07), and BMI (0·11 kg/m2, −0·09 to 0·30). Interpretation PCSK9 variants associated with lower LDL cholesterol were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-hip ratio, and an increased risk of type 2 diabetes. In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits of PCSK9 inhibitor treatment, as was previously done for statins. Funding British Heart Foundation, and University College London Hospitals NHS Foundation Trust (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | LifeLines Cohort study group; UCLEB consortium; Humans; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease; Blood Glucose; Case-Control Studies; Cohort Studies; Cholesterol, LDL; Randomized Controlled Trials as Topic; Genetic Variation; Mendelian Randomization Analysis; Proprotein Convertase 9 |
| Subjects: | H Social Sciences > H Social Sciences (General) R Medicine > R Medicine (General) |
| Divisions: | Faculty of Science and Health Faculty of Social Sciences Faculty of Science and Health > Mathematics, Statistics and Actuarial Science, School of Faculty of Social Sciences > Institute for Social and Economic Research |
| SWORD Depositor: | Unnamed user with email elements@essex.ac.uk |
| Depositing User: | Unnamed user with email elements@essex.ac.uk |
| Date Deposited: | 02 Dec 2016 15:26 |
| Last Modified: | 30 Oct 2024 20:25 |
| URI: | http://repository.essex.ac.uk/id/eprint/18320 |
Available files
Filename: 1-s2.0-S2213858716303965-main.pdf
Licence: Creative Commons: Attribution 3.0